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Abstract
Background Skeletal muscle dysfunction in patients with
heart failure (HF) has been linked to impaired growth hor-
mone (GH)/insulin-like growth factor (IGF)-1 signaling. We
hypothesized that ventricular assist device (VAD) implanta-
tion reverses GH/IGF-1 axis dysfunction and improves mus-
cle metabolism in HF.
Methods Blood and rectus abdominis muscle samples were
collected during VAD implantation and explantation from
patients with HF and controls. Clinical data were obtained
from medical records, biomarkers measured by enzyme-
linked immunosorbent assay (ELISA), and gene expression
analyzed by reverse transcription and real-time polymerase
chain reaction (RT-PCR). Grip strength was assessed by dy-
namometry. Oxidative capacity was measured using oleate
oxidation rates. Muscle fiber type and size were assessed by
histology.
Results Elevated GH (0.27±0.27 versus 3.6±7.7 ng/ml in
HF; p=0.0002) and lower IGF-1 and insulin-like growth
factor binding protein (IGFBP)-3 were found in HF (IGF-1,
144±41 versus 74±45 ng/ml in HF, p<0.05; and IGFBP-3,
3,880±934versus1,935±862ng/mlinHF,p=0.05).TheGH/
IGF-1 ratio, a marker of GH resistance, was elevated in HF
(0.002±0.002 versus 0.048±0.1 pre-VAD; p<0.0039). After
VAD support, skeletal muscle expression of IGF-1 and
IGFBP-3 increased (10-fold and 5-fold, respectively;
p<0.05) accompanied byenhancedoxidative geneexpression
(CD36, CPT1, and PGC1α) and increased oxidation rates (+
1.37-fold; p<0.05). Further, VAD implantation increased the
oxidative muscle fiber proportion (38 versus 54 %, p=0.031),
fiber cross-sectional area (CSA) (1,005±668 versus 1,240±
670 ʼm
2, p<0.001), and Akt phosphorylation state in skeletal
muscle. Finally, hand grip strength increased 26.5±27.5 % at
180 days on-VAD (p<0.05 versus baseline).
Conclusion Our data demonstrate that VAD implantation cor-
rects GH/IGF-1 signaling, improves muscle structure and
function, and enhances oxidative muscle metabolism in pa-
tients with advanced HF.
Keywords Skeletalmuscle .Heartfailure .Cardiovascular
surgery .Metabolism .Growthfactors
Metabolic abnormalities develop in patients with advanced
heart failure (HF) and impact every organ system [1–3]. End-
stage HF is associated with a catabolic state that affects both
systemic and local metabolism, leading to a negative protein
balance driven by increased energy expenditure. Skeletal
muscle, the largest reservoir of protein, is prone to wasting
in catabolic states including HF. Exercise intolerance, a clin-
ical hallmark of patients with HF, is determined not only by
impaired central hemodynamics but also by peripheral abnor-
malitiesinskeletalmusclemetabolism,structure,andfunction
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DOI 10.1007/s13539-014-0155-9[4–6]. These intrinsic skeletal muscle changes have been
linked to endocrine and paracrine abnormalities [1], increased
oxidativestress[7],impairedintramuscularCa
2+handling[8],
and reduced capillary density [9].
A major anabolic system of the human body is the growth
hormone (GH)/insulin-like-growth factor (IGF)-1 signaling axis
with well-established effects on muscle mass and function and
in the regulation of lipolysis and lipid oxidation [10]. Growth
hormone resistance with inappropriately low levels of IGF-1
develops in chronic inflammatory states and is associated with
catabolic syndromes including advanced HF [11, 12]. Growth
hormone resistance has been linked to inflammation tumor
necrosis factor-alpha- and interleukin-6-mediated inhibition of
hepatic GH signaling as well as levels of angiotensin II [13].
Therapeutic interventions to address progressive catabo-
lism in advanced HF are limited. Interventions known to
increase circulating IGF-1 levels and increase muscle mass
in HF are GH supplementation and aerobic exercise training
[14, 15], and GH resistance resolves following cardiac trans-
plantation [16]. Improvements in systemic and local metabo-
lism have also been linked to corrected hemodynamics and
tissue perfusion following the implantation of ventricular
assistdevicesinpatientswithadvancedHFbothasdestination
therapy and as bridge-to-transplantation [17, 18]. Multiple
studies have shown that ventricular assist device (VAD) im-
plantation not only provides adequate hemodynamic support
but is also effective in rehabilitating patients based on im-
proved renal and hepatic function as well as physical capacity
assessments [19–22]. We, therefore, hypothesized that im-
plantation of a VAD would improve skeletal muscle function
and metabolism and reverse GH/IGF-1 axis dysfunction in
patients with HF.
1M e t h o d s
1.1 Study design
We analyzed a cohort of 31 patients with advanced HF under-
going VAD implantation (n=25) and explantation (n=25).
Data from 19 patients were available both at the time of
VAD implantation and explantation for paired analyses. All
patients underwent continuous flow VAD implantation
(Heartmate II, Thoratec Inc.) at Columbia University
Medical Center between August 2010 and April 2012.
Controls (n=10) were recruited among healthy volunteers at
ourinstitution.Controlswereexcludediftheyhadevidenceof
diabetes, inflammatory diseases, hyperlipidemia, renal dys-
function, or liver dysfunction. We collected standard clinical
information, medical history, clinical laboratory data, and
echocardiographic data for all patients and control subjects
from electronic medical records or through direct analysis.
The study was approved by the Institutional Review Board
of Columbia University, and all patients provided written
informed consent before inclusion into the study.
1.2 Sample collection
Fasting blood samples were collected from all study subjects
(31 patients with HF and 10 controls). Paired serum samples
(pre-VAD and post-VAD) were available from 19 patients.
Rectus abdominis muscle samples were collected during sur-
gical VAD implantation and at explantation during cardiac
transplantation from 12 non-paired patients.
1.3 Grip strength analysis
Grip strength was measured with a hand dynamometer (Jamar,
Inc.) in a subgroup of 15 patients at baseline and at various time
points up to 180 days following VAD implantation. While
resting the elbows on the hips, the patients were asked to
squeeze the dynamometer at maximum force (three repetitions
10 s apart for both dominant and non-dominant hands). Values
from the dominant and non-dominant arm were averaged and
normalized for body weight to exclude weight-related differ-
ences. Dynamics are reported as percent changes from baseline.
1.4 Serum analysis
Samples were centrifuged at 10,000×g and stored at −80 °C
until analysis. Serum samples were analyzed using enzyme-
linked immunosorbent assays (ELISAs) to measure the serum
levels of GH, IGF-1, and insulin-like growth factor binding
protein (IGFBP)-3 (Quantikine, R&D Systems, Minneapolis,
MN, USA).
1.5 Gene expression analysis
Total RNAwas extracted from rectus abdominis muscle sam-
ples (n=10) using the phenol-chloroform RNA extraction
method. RNA was then used to prepare complementary
DNA (cDNA) with the Superscript reverse transcriptase
cDNA kit (Invitrogen), and the abundance of the specific
mRNAs was determined by reverse transcription and real-
time polymerase chain reaction (RT-PCR) (Bio-RAD) using
previously described primers (IGF-1, IGFBP3, IGF receptor,
CD36, CPT1, GLUT4, PDK4, PGC1α)[ 23]. Gene expres-
sion was normalized using expression of beta-actin and
expressed as relative expression.
1.6 Histological analysis
Muscle fiber cross-sectional area (CSA) and capillary density
were analyzed in a subsetof six patientsbefore and after VAD
implantation using previously described methods [24]. In
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cle samples were reviewed microscopically at ×10 magnifica-
tion (Nikon Eclipse E 200) and on three independent images
per slide, fiber size and capillaries were analyzed using stan-
dard image-processing software (NIH ImageJ). Capillaries
were detected by immunohistochemistry using specific anti-
bodies for detection of E-selectin (Santa Cruz, Inc.).
Capillaries were counted on each image and expressed as
number of capillaries per muscle fiber. Muscle fibers were
only measured if their shape was not elongated to an ellipsoid
shape which would imply a sectioning not perpendicular to
the long axis. For all slides, the scale was set to 2.84 pixels/
unit based on a standardized stage micrometer for ×10 mag-
nification. Frequency histograms were constructed based on
the number of muscle fibers falling within CSA groups.
Immunohistochemistry was performed for the characteri-
zation of muscle fiber oxidative quality and fiber typing.
Paraffin-embedded sections (5 ʼm) were first incubated in
5 % goat serum to reduce non-specific immunoreactivity
andsubsequentlywithprimaryanti-myosinantibodies(mono-
clonal anti-fast twitch skeletal muscle myosin, Sigma, 1:400).
Specific immunoreactivity was detected with a secondary
rabbit anti-mouse antibody (Pierce, 1:400) followed by con-
jugation with avidin-biotin-complex (ABC Kit, Pierce).
Immunopositive fibers were quantified and expressed as per-
cent of all muscle fibers.
1.7 Fatty acid oxidation analysis
Fattyacidoxidation inmuscletissues was performed inrectus
abdominis muscle samples obtained from patients before and
after VAD implantation (n=6 per group) by measuring the
production of [
14C] CO2 from [
14C] oleic acid (PerkinElmer,
Waltham, MA). Approximately 20–30 mg of muscle tissues
was transferred into 10-mL Kontes® flasks (Sigma-Aldrich,
St. Louis, MO) containing 1 mL of modified Krebs Ringer’s
solution (115 mM NaCl, 2.5 mM KCl, 1.2 mM KH2PO4,
10 mM NaHCO3, 10 mM HEPES) with 1.5 % BSA,
0.2 mM oleic acid, 2 ʼCi/mL [
14C] oleic acid, and 1 mM
glucose. The flasks were immediately cupped with rubber
stoppers containing an attached central well with a 3×3 cm
filter paper soaked in 300 ʼLK O H .A f t e r1ho fi n c u b a t i o na t
37 °C, 200 ʼL of 70 % perchloric acid was injected into the
flask. The flasks were incubated for an additional 1 h at 37 °C
withshakingat70Hz.Thefilterpaperscontainingthetrapped
[
14C] CO2 were transferred to liquid scintillation tubes and
assessed for radioactivity in a liquid scintillation counter.
1.8 Statistical analysis
Data are presented as mean±standard deviation or as propor-
tion (percent). Normality was tested using the Kolmogorov-
Smirnov test. Group comparisons were made using the χ
2 or
Fisher’s exact test for categorical variables and the Student’s t
test or one-way analysis of variance with Tukey’s post hoc
testing for continuous variables. For variables that did not
follow a Gaussian distribution, the Mann-Whitney U test or
Kruskal-Wallis analysis of variance was used. Strength of
association between variables was assessed by either
Pearson or Spearman correlation, as appropriate. Data were
analyzed using GraphPad Prism 5.0 (La Jolla, CA). A p value
<0.05 was considered statistically significant.
2R e s u l t s
2.1 Baseline demographics
Clinical characteristics of all patients are summarized in
Table 1. Five patients (20 %) had a history of dilated
cardiomyopathy, 15 patients (60 %) had a history of
ischemic cardiomyopathy, and 5 (20 %) had other
causes of HF. Controls did not have any cardiac disease
and did not report a history of smoking or hypertension.
The mean duration of VAD support was 358±294 days.
BMI did not change significantly during the time of
VAD support. Laboratory values in patients with ad-
vanced HF before and after VAD placement and con-
trols are summarized in Table 2.
2.2 Serum markers of the GH/IGF-1 axis
TheserummarkersfortheGH/IGF-1axiswereanalyzedinall
subjects (Fig. 1). Serum levels of GH were higher in patients
with advanced HF (pre-VAD) compared to controls (0.27±
0.27 versus 3.6±7.7 ng/ml in advanced HF pre-VAD; p=
0.0002) while IGF-1 and IGFBP both were lower in HF
(IGF-1, 144±41 versus 74±45 ng/ml in advanced HF pre-
VAD, p<0.05; and IGFBP-3, 3,880±934 versus 1,935±
862 ng/ml in advanced HF pre-VAD, p=0.05). No changes
were found in IGF-1 or IGFBP3 serum levels after VAD
implantation. Circulating levels of GH decreased to 1.77±
2.9 ng/ml following VAD implantation (p=NS versus pre-
VAD). The GH/IGF-1 ratio, a marker of GH resistance, was
elevated in patients with advanced HF compared to
controls (0.002±0.002 in controls versus 0.048±0.1
pre-VAD; p<0.0039) and decreased numerically during
VAD support (0.032±0.065; p=0.2 versus pre-VAD).
No relation was found between duration of device sup-
port and changes in systemic or local GH/IGF-1 axis
parameters (coefficients of correlation: duration of left
ventricular assist device (LVAD) support vs. GH chang-
es R
2=0.0031, duration of LVAD support vs. IGF1
changes R
2=0.1925, duration of LVAD vs. GH/IGF-
ratio R
2=0.0149; all p=NS).
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Measurement of hand grip strength normalized for body
weight was performed in patients with advanced HF before
undergoing VAD implantation and in controls. Further, hand-
grip strength was measured at various time points after the
VAD implantation. The readings were taken for both the
dominant and non-dominant hands and averaged. Patients
with advanced HF had lower handgrip strength corrected for
bodyweightpriortoVADimplantation(35.8±7.8versus55.6
±12.7incontrols;p=0.001). There was a relative increase in
the average handgrip strength normalized for BW over time
reaching >25 % after 6 months on-VAD support (2 months +
12.8±20.7%,4months+18.9±21.4%,and6months+26.5±
27.5 % of baseline pre-VAD; p<0.05 versus baseline) (Fig. 2).
2.4 Analysis of skeletal muscle gene expression following
VAD implantation
The local skeletal muscle expression of anabolic IGF-1 in-
creased 15-fold (p=0.047), and expression of IGF binding
p r o t e i n( B P ) - 3d e m o n s t r a t e dat r e n dt o w a r d sa ni n c r e a s e( p=
0.06) in response to hemodynamic improvement by VAD
implantation. Expression of the IGF receptor in skeletal muscle
decreased following VAD implantation (p=0.048) (Fig. 3a).
We next analyzed the expression of marker genes of glu-
cose and fatty acid metabolism. The expression of the insulin-
dependent glucose transporter type 4 (GLUT4) increased in
muscle samples (+6.7-fold versus pre-VAD, p=0.046)impli-
cating increased glucose transport capacity following VAD
implantation. Pyruvate dehydrogenase kinase-4 (PDK-4) de-
creased by 50 % during VAD support (p=NS). Of note,
skeletal muscle expression levels of the scavenger receptor,
cluster of differentiation (CD) 36, and the mitochondrial fatty
acid uptake transporter, carnitine palmitoyl transferase (CPT)-
1, both genes indicative of fatty acid oxidative metabolism,
increased significantly (CD36, +3-fold and CPT1, +3.5-fold,
both p<0.05 versus pre-VAD). Finally, expression levels of
peroxisome proliferator-activated receptor ʳ co-activator-1α
(PGC1α), a master regulator of oxidative metabolism, in-
creased 3.2-fold following VAD implantation in rectus
abdominis muscle of patients with advanced HF (p=0.03
versus pre-VAD; Fig. 3b).
2.5 Analysis of skeletal muscle histology and oxidative
capacity
Histological analysis of skeletal muscle specimens obtained
from patients before and after VAD implantation revealed an
increase in muscle fiber cross-sectional area following VAD
implantation(meanCSA,1,005±668versus1,240±670ʼm
2,
Table 1 Baseline demographics
Controls VAD
implant
VAD
explant
(n=10) (n=25) (n=25)
Age at VAD implantation
(years)
62±7 64±7 62±8
Gender (% male) 9 (90) 22 (88) 21 (84)
BMI (kg/m
2) 25.2±2.9 26.8±4.3 25.6±3.5
Etiology of HF
DCM 5 (20)
ICM 15 (60)
Other 5 (20)
Treatment (no. of patients, %)
Diuretics – 18 (72) 16 (64)
ʲ-blockers – 16 (64) 20 (80)
ACE inhibitors/AII
antagonists
– 12 (48) 12 (48)
Coumadin – 9 (36) 13 (52)
Table 2 Dynamics of laboratory values during VAD support
Control (n=10) VAD implant (n=25) VAD explant (n=25)
White blood cell count (×10
3/ʼL) 5.1±0.3 8.7±3.5 8.5±4.1
Hematocrit (%) 40.2±5.7 28.2±10.2* 31.7±4.6
Platelets (×10
3/ʼL) 217±17 203±85 178±73
Sodium (mEq/L) 140±12 135±4 138±4
Blood urea nitrogen (mg/dL) 18±4 33±16* 25±11
Creatinine (mg/dL) 1.0±0.2 2.5±5.3 1.3±0.6
Albumin (mg/dL) 4.7±0.4 3.5±0.5* 3.7±0.5
†
Total bilirubin (mg/dL) 0.6±0.2 1.6±1.8 1.1±0.9
Direct bilirubin (mg/dL) 0.1±0.0 0.6±1.0 0.5±0.5
Aspartate aminotransferase (U/L) 25±10 36±27 56±56
Alanine transaminase (U/L) 25±7 29±25 25±22
Alkaline phosphatase (U/L) 72±15 89±36 76±30
*p<0.05 between implants and controls;
†p<0.05 between explants and controls
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sectional area shows a distinct right shift in the percentage of
fibers with greater cross-sectional area following VAD place-
ment indicating larger muscle fibers. Further, immunohisto-
chemistry using an antibody against fast-twitch, glycolytic
myosin showed a high proportion of glycolytic type II muscle
fibers in the rectus abdominis muscle samples from patients
with advanced HF before VAD placement. Hemodynamic
correctionfollowingVADplacementdecreasedtheproportion
ofglycolytictype IIfiberswitha relativeincreaseofoxidative
type I muscle fibers (type I/type II fiber, 38/62 % pre-VAD
versus 54/46 % post-VAD, p=0.031)(Fig.4b).
Skeletal muscle capillary density analysis did not show
significant differences in the number of capillaries per muscle
fiber in response to VAD implantation (mean number of
capillaries per muscle fiber ratio, 0.34±0.05 pre-VAD versus
0.3±0.06 post-VAD; p=0.6).
Fatty acid oxidation analysis of skeletal muscle tissue from
patients before and after VAD implantation showed an in-
crease in the production of [
14C] CO2 from [
14C] oleic acid
followingVADimplantation(+1.37-fold versuspre-VAD;p=
0.03)(Fig.4c).Thiswasaccompaniedbyincreasedphosphor-
ylation of Akt in skeletal muscle of patients following VAD
support compared to pre-VAD implantation (+2.3-fold versus
pre-VAD; p<0.01) (Fig. 4d).
3 Discussion
In our current study, we demonstrate that patients with ad-
vanced HF develop GH resistance characterized by elevated
circulating GH and reduced IGF-1 levels. Following mechan-
ical unloading of the failing myocardium and subsequent
hemodynamic normalization, improvement of GH resistance
was found accompanied by enhanced local expression of
anabolic IGF-1 in skeletal muscle. Further, VAD implantation
increased skeletal muscle fiber CSA and improved skeletal
muscle oxidative function. These profound anabolic and ox-
idative changes are accompanied by improved systemic and
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Fig.1 Serum markers ofthe GH/
IGF-1 axis in patients with
advanced HF before and after
VAD implantation and controls. a
Levels of GH in HF were higher
compared to controls and
remained elevated after VAD
implantation. b Suppression of
circulating IGF-1 in advanced HF
compared to controls without
changes following VAD
implantation. c Changes in the
GH/IGF-1ratioshowedimproved
GH sensitivity following VAD
placement. d IGFBP3 was lower
in advanced HF compared to
controls with or without changes
following VAD placement
(*p<0.05 versus controls,
#p<0.05 versus pre-VAD; 10
controls,25patientspre-VADand
post-VAD for all measures)
Fig. 2 Functional analysis of skeletal muscle. Hand grip strength im-
proved by around 20 % of baseline pre-VAD values at 90 days following
surgery with further increase over the following weeks (*p<0.05versus
baseline, n=15 patients at baseline, solid line—dominant hand, dashed
line—non-dominant hand)
J Cachexia Sarcopenia Muscle (2014) 5:297–305 301local metabolic function and increased skeletal muscle hand
grip strength.
Skeletal muscle metabolism, morphology, and function are
the resultofa dynamic networkofpathways thatare knownto
be deranged in patients with advanced HF [5, 6]. The meta-
bolic phenotype of skeletal muscle is determined by the rela-
tive composition of enzymes and contractile protein isoforms
of its individual fibers; therefore, any quantifiable fiber plas-
ticity is reflective of underlying molecular metabolic changes
[5]. Reduced oxidative capacity of skeletal muscle is associ-
ated with decreased type I oxidative fibers, increased glyco-
lytic type II fibers, mitochondrial dysfunction, and induction
of muscle atrophy [25]. Reduction of capillary density in HF,
poor peripheral perfusion, and impaired nutritional status fur-
ther contribute to these changes [4, 9]. Of note, glycolytic
generation of ATP results in reduced net production of ATP
compared to oxidation of glucose and fatty acids in the mito-
chondria, leading to energy depletion and decreased glycogen
content ofskeletalmuscleinadvancedHF [5].Thisperipheral
skeletal muscle phenotype mimics the known changes in
energy metabolism in the failing myocardium.
The current study shows a profound effect of VAD implan-
tation on the GH/IGF-1 signaling axis. However, while the
GH/IGF-1 ratio improved, the circulating levels of both GH
and IGF-1 were not normalized and still showed significant
abnormalities compared to controls. The function of this en-
docrine system isseverely deranged in advanced HF with loss
of pulsatile GH secretion and development of GH resistance
[11], reduced IGF-1 levels [12, 26], and impaired local ex-
pressionofIGF-1[12,24].Dysfunctionofthismajor anabolic
system is known to be associated with loss of body weight,
muscle wasting, and impaired survival [10]. Previous trials of
GH supplementation in patients with HF have been neutral in
outcome or negative [14]. No large clinical trial has evaluated
the role of IGF-1 supplementation in HF due to the known
proliferative and neoplastic effects of this molecule which,
however, might be overcome by synthetic analogues of regu-
lators and mediators of the GH/IGF-1 axis [10, 27].
The impact of local IGF-1 as a mechanosensitive factor of
muscle growth has been studied in various animal models and
humans[12,13, 15,28].Muscledenervation,immobilization,
and atrophy are all associated with dysfunction of the IGF-1
intracellular signaling cascade [28, 29]. Its molecular result is
an induction of ubiquitin-dependent proteolysis, and con-
versely, overexpression orfunctionalinduction ofIGF-1leads
to suppression of levels of several ubiquitin E3 ligases [24,
28]. Therefore, IGF-1 and its associated signaling events
represent a critical molecular switch mechanism in the bal-
ancedregulationofcellulargrowthandatrophywithprofound
effects on tissue homeostasis when being dysregulated. Of
note, our group has previously shown that both transgenic
overexpression of local IGF-1 in skeletal muscle in mice [24]
and exercise-induced upregulation of IGF-1 in humans [9]
prevent muscle atrophy and impaired metabolism in HF.
Based on our analysis, it is not entirely clear how skeletal
muscle oxidative function and local expression of IGF-1
improve following VAD implantation. One hypothesis is that
increased mobility of patients with HF following VAD im-
plantation leads to increased muscle activity and, therefore,
results from an exercise-like effect on muscle metabolism and
structure. On the other hand, improved nutritional status with
better absorption of nutrients, increased appetite, and reduced
insulin resistance following VAD implantation might affect
peripheral skeletal muscle metabolism. Nevertheless, in our
cohort, mean BMI did not change significantly following
VAD implantation, in contrast to other studies that have re-
ported increases in BMI following VAD implantation in some
patients[30].Inarecentstudy,Emanietal.[31] analyzedBMI
characteristics derived from the HeartMate-II clinical trial
studies database and describe a significant increase of BMI
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Fig. 3 Analysis of anabolic and metabolic marker gene expression in
skeletal muscle before and after VAD implantation. a VAD placement
results in increased expression of anabolic IGF-1 in skeletal muscle.
IGFBP3 remained unchanged while levels of IGF-1 receptor decreased.
b Analysis of markers of glucose and fatty acid uptake and oxidation in
skeletal muscle before and after VAD implantation showed increased
expression of GLUT4 following VAD with a non-significant decrease
in PDK4. The fatty acid transporter CD36 and the mitochondrial marker
of fatty acid uptake, CPT1, both increased as well. Finally, PGC1α,t h e
master regulator of oxidative metabolism, increased in skeletal muscle
following VAD placement indicating overall increased oxidative metab-
olism (*p<0.05 versus pre-VAD; n=6–10 per group for all measures;
gene expression based on normalization to beta-actin; empty bars—pre-
VAD, filled bars—post-VAD)
302 J Cachexia Sarcopenia Muscle (2014) 5:297–305in patients during VAD support, mainly in underweight pa-
tients. Our studywas not ableto reproduce thisfinding,which
might be owed to the considerably smaller number of patients
included in our study and differences in baseline BMI before
VAD implantation. In the comparable group of the study of
Emani et al., in the category “normal” BMI (18.5–29.9 kg/
m
2), the mean BMI was 24±3 kg/m
2 while in our study, the
mean BMI was 26.8±4.3. Emani et al. reported a small
although significant increase of BMI of less than 5 % at
6 months after VAD implantation. However, in the cohort
assigned to the “obese” category (mean BMI 32±1 kg/m
2),
no significant difference of BMI could be observed at 6 and
24 months after VAD implantation. Furthermore, only 9 % of
the patients originally included in the study were analyzed for
BMI changes at the 24-month time point which raises the
concern of survivor bias in that analysis. Finally, improved
peripheral circulation, increased tissue perfusion, and reduced
hypoxia both at rest and during exercise appear to contribute
to the increased oxidative metabolism in skeletal muscle. Our
current study, however, did not show a significant difference
in capillary density in skeletal muscle during VAD implanta-
tion. Several studies have shown the induction of glycolytic
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Fig. 4 Analysis of skeletal
muscle before and after VAD
implantation. a Left, analysis of
muscle fiber cross-sectional area
onH&E-stainedsectionsofrectus
abdominis muscle specimens.
Muscle fiber cross-sectional area
increased following VAD
placement. Right, fiber size
distribution diagram (n=6
samples before and after VAD
implantation). b VAD
implantation is associated with
increased number of oxidative
type I muscle fibers. Left,
immunohistochemical analysis of
type II myosin (dark fibers)
reveals a decreased proportion
consistent with improved
oxidative capacity following
VAD placement (p<0.05).
Oxidative type I fibers are non-
stained muscle fibers. Right,
quantitative analysis of type I
versus type II muscle fibers in
skeletal muscle before and after
VAD implantation (n=6 per
group; p=0.04)c VAD
implantation results in increased
fatty acid oxidation, assessed by
increased [
14C] CO2 production
in skeletal muscle following VAD
placement (p<0.05;n=6 per
group). d Increased Akt
phosphorylation in skeletal
muscle post-VAD implantation
(n=6 per group; p=0.012 versus
pre-VAD)
J Cachexia Sarcopenia Muscle (2014) 5:297–305 303metabolism at the cost of oxidative ATP generation in the
setting of hypoxia in various tissues. The underlying mecha-
nism seems to be a molecular cross talk between an induction
of hypoxia-induced factor (HIF)-1α and reduced expression
and activity of the master regulator of oxidative metabolism,
PGC-1α [32]. Consistently, VAD support increased skeletal
muscle PGC-1α levels.
Metabolic marker genes and their expression levels are
indicative of the distinct metabolic phenotype of skeletal
muscle. Induction in GLUT4 following VAD implantation
suggests increased insulin-regulated glucose transport capac-
ity within myocytes. Increased expression of CD36, the fatty
acids transporter, and CPT-1, the rate-limiting transporter
controlling fatty acid uptake to mitochondria, in skeletal mus-
cleafterVADimplantationimpliesimprovedfattyaciduptake
and oxidation. These changes are consistent with an
increased oxidative capacity and increased lipid oxida-
tion rate of skeletal muscle following VAD implantation.
Of note, a negative feedback loop seems to involve the
expression of the IGF-1 receptor where increased levels
of circulating and local IGF-1 are associated with de-
creased expression of IGF-1 receptor in skeletal muscle
following VAD implantation. Nevertheless, increased
phosphorylation of Akt in skeletal muscle following
VAD implantation indicates increased PI3kinase/Akt sig-
naling downstream of the IGF-1 receptor.
Therapeutic interventions to affect skeletal muscle dys-
function in HF are very limited. No medical therapy targeting
muscle dysfunction or metabolism in HF has been established
so far, and only exercise training has been consistently linked
to improved peripheral muscle metabolism, structure, and
function [4]. Exercise training also leads to increased exercise
capacity and improved quality of life in patients with
HF [9, 11, 12]. Of note, several studies have shown
increased oxidative capacity, improved mitochondrial
function, reduction in fiber atrophy, as well as increased
expression of IGF-1 following exercise training in pa-
tients and animal models of HF [4].
Our study is limited by the small sample size and the
smaller size of cohorts analyzed in the subsets for histologic
and molecular measurements due to tissue collection variabil-
ity. Therefore, the analysis power of these subsets is smaller
than the larger complete cohort.
In conclusion, our data demonstrate that mechanical
unloading of the failing myocardium with hemodynamic im-
provement after VAD implantation leads to correction of GH
resistance and increased local levels of IGF-1 in patients with
advanced HF. Further, muscle function, oxidative capacity,
and ultrastructure improve after VAD implantation. These
findings demonstrate that VAD support is associated with a
partial correction of metabolic and functional abnormalities of
skeletal muscle and impaired GH/IGF-1 signaling in patients
with advanced HF.
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